GlycoMimetics Initiates First Clinical Trial of GMI-1271 as Potential Treatment for Blood-Related Cancers
- E-selectin antagonist, GMI-1271, also has the potential to reduce complications of chemotherapy -
"We have demonstrated a very attractive preclinical profile for
GMI-1271, with research findings substantiating the focus on E-selectin
as a potential target for blood-related malignancies and for solid
tumors at risk of metastasis," said
This single-site Phase 1 trial of GMI-1271, is a randomized, double-blind, placebo-controlled, single ascending intravenous dose study designed to evaluate the safety, tolerability and pharmacokinetics of GMI-1271 in 28 healthy adult subjects (three dose levels will be tested). The company anticipates final data being available in the second half of 2014. The company's next planned study is a Phase 1/2 trial of GMI-1271 as an adjunct to standard chemotherapy in patients with AML.
About AML
Adult acute myeloid leukemia (AML) is a cancer of the blood and bone marrow. AML is the most common type of acute leukemia in adults, and it is estimated that there will be over 18,000 new cases and over 10,000 deaths from the disease in 2014. Unlike other cancers that start in an organ and spread to the bone marrow, AML is known for rapid growth of abnormal white blood cells that gather in the bone marrow and in most cases move into the blood, getting in the way of normal blood cell production. The lack of normal blood cells can cause some of the symptoms of acute myeloid leukemia, including anemia (shortage of red blood cells resulting in tiredness and weakness), neutropenia (shortage of white blood cells that may lead to increased infections), and thrombocytopenia (shortage of platelets in the blood that may lead to excessive bleeding). Current treatment options for AML consist of reducing and eliminating cancer cells mainly through chemotherapy, radiation therapy, and stem cell transplantation.
About
Cautionary Note on Forward Looking Statements
Any statements in this press release about future expectations, plans
and prospects for
bhahn@glycomimetics.com
Source:
News Provided by Acquire Media